ERBB2 and breast carcinoma: But phase III SANDPIPER trial showed the addition of taselisib to fulvestrant for oestrogen receptor‐positive, HER2‐negative, PI3KCA‐mutant, advanced breast cancer was not suggested given its toxicities and modest clinical benefit.358